Quantcast

Latest Valeant Pharmaceuticals Stories

2014-06-11 08:24:52

Editor Note: For more information about this release, please scroll to bottom. LONDON, June 11, 2014 /PRNewswire/ -- On Tuesday, June 10, 2014, the NASDAQ Composite ended at 4,338.00, up 0.04%, the Dow Jones Industrial Average finished the day 0.02% higher at 16,945.92, and the S&P 500 closed at 1,950.79, down 0.02%. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 692.83, up...

2014-06-09 08:29:29

LONDON, June 9, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Canada Pharmaceuticals and Healthcare Report Q3 2014http://www.reportbuyer.com/pharma_healthcare/therapeutic/canada_pharmaceuticals_healthcare_report_q3_2013_1.html Includes 3 FREE quarterly updatesBMI View: The Canadian pharmaceutical and healthcare market will become increasingly attractive to pharmaceutical companies over the next few years as economic growth in the country gradually...

2014-06-09 04:21:23

LAVAL, Quebec, June 9, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that that its wholly owned subsidiary, Valeant Pharmaceuticals North America LLC, received notice that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Jublia(®) (efinaconazole 10% topical solution), the first topical triazole approved for the treatment of onychomycosis of the toenails. "We acquired Jublia(®)...

2014-05-30 16:24:44

- Cash of $72.00 per share and 0.83 Shares of Valeant stock LAVAL, Quebec, May 30, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that it is making an offer for Allergan, Inc. (NYSE: AGN) under which each Allergan share would be exchanged for $72.00 in cash and 0.83 shares of Valeant common stock, based on the fully diluted number of Allergan shares outstanding. This offer is subject to prompt good faith negotiation of a...

2014-05-28 12:32:31

- Galderma positioned to commercialize Restylane®, Perlane®, Emervel®, Sculptra®, Dysport® in the U.S. and Canada FORT WORTH, Texas, May 28, 2014 /PRNewswire/ -- Galderma Laboratories, L.P. ("Galderma") announced today that Nestle S.A., Switzerland, one of Galderma's shareholders, has entered into an agreement with Valeant Pharmaceuticals International, Inc. and related entities ("Valeant"), through which Galderma will become the distributor of several key products in...

2014-05-28 08:30:03

LAVAL, Quebec, May 28, 2014 /PRNewswire/ -- -- Increases Cash Consideration by $10.00 per share to $58.30, approximately 21 Percent Increase -- Maintains 0.83 of a Valeant share -- Adds Contingent Value Right for DARPin of up to $25.00 per Share in Value -- Valeant Commits to Invest up to $400 Million in DARPin and Retain Current Allergan Employees Responsible for Development -- Represents 40 Percent of DARPin Net Sales after...

2014-05-28 00:21:31

LAVAL, Quebec, May 28, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it has entered into an agreement with Nestle S.A. to sell all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash. Nestle expects to complete its acquisition of Galderma S.A. in July and would expect to operate the acquired assets through Galderma. The transaction is subject to customary closing...

2014-05-27 20:22:14

LAVAL, Quebec, May 27, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) announced today that the company is hosting an in-person meeting for Allergan and Valeant shareholders tomorrow at 8:00 a.m. ET (5:00 a.m. PT) at the AXA Equitable Auditorium, 787 Seventh Avenue (between 51st and 52nd Streets), New York, New York to respond to assertions Allergan has made that the Valeant model is not sustainable, that the Bausch + Lomb portfolio is not...

2014-05-27 12:32:51

DUBLIN, May 27, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/mkpzcg/global_glaucoma) has announced the addition of the "Global Glaucoma Therapeutics Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Glaucoma is a disease of the eye in which fluid pressure within the eye increases. If left untreated the patient may lose vision and even become blind. The exact etiology of optic nerve damage due to glaucoma is...

2014-05-23 08:24:05

LAVAL, Quebec, May 23, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced members of its senior management team will make a presentation at the Sanford C. Bernstein Thirtieth Annual Strategic Decisions Conference 2014 on Wednesday, May 28, 2014 at 4:00 p.m. ET. The conference will be held at The Waldorf Astoria in New York. A live webcast and audio archive of the presentation will be available on the company's Web site at...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related